Editorial content

Deals round up - January 22nd - 29th

The past week has seen another major M&A deal for the year and it’s not even the end of January.

Go to the profile of Raveena Bhambra
Jan 29, 2018
1
0
Like 1 Comment

The past week has seen another major M&A deal for the year and it’s not even the end of January.

Today, it has been announced that Sanofi is to acquire the nanobody platform company Ablynx in a deal worth almost €4 billion. Ablynx will bring a pipeline of over 45 candidates, 8 of which are in clinical development and one of which, caplacizumab is filed in Europe for acquired thrombotic thrombocytopenia purpura. Novo Nordisk were keen to purchase Ablynx a couple of weeks ago, bidding around €2.6 billion for the company, but lost out to Sanofi, which has only just announced its $11.6 billion acquisition of haematology company Bioverativ (see last week’s round up).

Novartis has signed a $170 million licensing deal with Spark Therapeutics to develop and commercialise the newly US FDA-approved gene therapy Luxturna (voretigene neparvovec-ryzl) outside the US. Spark will continue to manage the European approval process for this pioneering therapy for the rare eye disease Leber congenital amaurosis, and will receive a $105 million upfront fee from Novartis.

And finally, Biogen has signed a potential $217 million deal (including a $10 million upfront payment) to acquire KPT-350 and other undisclosed assets from Karyopharm. KPT-350 is an inhibitor of XPO1, which mediates the nuclear export of multiple proteins. The small-molecule compound has shown potential in preclinical studies to treat both neurological and inflammatory conditions, and is ready for filing of an investigational new drug application.

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Publishing Group

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 12 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.